key: cord-0747930-ceab6yjj
authors: Hanzel, Jurij; Ma, Christopher; Marshall, John K.; Feagan, Brian G.; Jairath, Vipul
title: Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies
date: 2020-05-05
journal: Clin Gastroenterol Hepatol
DOI: 10.1016/j.cgh.2020.04.033
sha: 938334cd4d08867f17b041b2a6a806fb7aecc4ed
doc_id: 747930
cord_uid: ceab6yjj

nan

We read the recent paper by Ungaro et al. 1 with great interest. As the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to spread, gastroenterologists managing patients with inflammatory bowel disease (IBD) face uncertainty amid growing patient concerns regarding risks associated with immunosuppressive medications. Descriptions of initial patient cohorts from China did not include details about concomitant immunosuppressive therapy because immune-mediated diseases did not feature prominently among the reported comorbidities. 2 Based upon these cohorts, the most important factors associated with poorer outcomes were older age, diabetes, hypertension and other cardiovascular disease.

An international registry of IBD patients with COVID-19 was established (SECURE-IBD,

April 2020, 382 cases were reported to the registry, of whom 106 had required hospitalization, and 13 had died. In the absence of data to inform decision making, several societies have proposed empiric guidelines for management of IBD patients. These recommendations should be considered in parallel with national/regional guidance from public health authorities, which include instructions for self-isolation that may substantially impact patient livelihoods and thus extend beyond the typical remit of guidelines for disease management. In the context of the rapidly evolving data, we summarize available recommendations from different gastroenterological societies.

To date, public guidance on the management of IBD patients during the COVID-19 pandemic has been issued by the British Society of Gastroenterology (BSG), 4 Crohn's and Colitis Canada (CCC), 5 European Crohn's and Colitis Organization (ECCO), 6, 7 

Organization for the Study of Inflammatory Bowel Disease (IOIBD) 8 (Table 1) .

All aforementioned societies recommend continuing IBD-specific treatment as risk of active disease was perceived to be higher than the uncertain risks of immunosuppression predisposing to higher risk of infection with SARS-CoV-2. Minimizing corticosteroid exposure by rapid tapering whenever possible is universally recommended, with the BSG additionally suggesting topical corticosteroids or exclusive enteral nutrition as alternatives for patients experiencing a flare. Thiopurine initiation is discouraged by both the BSG and 

Under Research Exclusion

Crohn-s-Colitis/COVID-19-and-IBD

COVID-19 ECCO Task Force

COVID-19 ECCO Task Force

Elective switching from intravenous to subcutaneous not recommended JAK inhibitors • No evidence of increased risk of COVID-19

• Continue treatment • Continue treatment • Avoid initiation if alternative available • Withhold until resolution if SARS-CoV-2 infection develops • Continue treatment • Withhold until resolution in case of

• Defer surveillance • Consider alternative methods of disease assessment